Skip to main content

Tweets

WATCH: TMP SMX Prophylaxis in GPA https://t.co/JtIjgxwrCf https://t.co/Tmzdu00oyH
Dr. John Cush @RheumNow ( View Tweet )
2 years 2 months ago
The SMART Study: Split Dose Oral Methotrexate Dr. Jack Cush discusses abstract 1583 presented at the 2023 ACR Convergence meeting in San Diego. https://t.co/Blg4EUe5rX https://t.co/0svgLAZ1as
Dr. John Cush @RheumNow ( View Tweet )
2 years 2 months ago
An Interview with Kevin Winthrop: Three Questions About COVID 19 Drs. Jack Cush and Kevin Winthrop discuss COVID 19 at 2023 ACR Convergence in San Diego, CA. https://t.co/UL8q356G3i https://t.co/wWsEHz9obA
Dr. John Cush @RheumNow ( View Tweet )
2 years 2 months ago
JAKi and TYK2i: What/when to use? You can see that the JAKi/TYK2i have both approved or potential seropositive and seronegative indications. There are also improvements in PsO for the class and studies in CTDs. It is difficult to know which to choose https://t.co/uid38oFBXP https://t.co/gLJfJNi2Jh
Dr. John Cush @RheumNow ( View Tweet )
2 years 2 months ago
Swedish national cohort study cohort study suggests #RA pts at incr risk for Autoimmune thyroid Dz, but decreases after RA Dx & Rx. n=13,731 RA vs 63,201 matched pop. controls. Lower rates AITD w/ biologics & TNFi (HR 0.54, 0.67) https://t.co/ZfputgDJQE https://t.co/Z1r0eGFcX9
Dr. John Cush @RheumNow ( View Tweet )
2 years 2 months ago
Last chance for early bird savings! Our early bird special closes on 11/30. Join us for RheumNow Live THIS JANUARY! https://t.co/uD01S8rgrh https://t.co/29u3wz5PHK
Dr. John Cush @RheumNow ( View Tweet )
2 years 2 months ago
National pharmacovigilance database review (1992 to 2021) identified 2217 "Falls", most serious, most in women (61%), & 38% in 18–64 yr olds. Falls attributed to immunomodulators (17%), 24% Fxs & 1 in 7 classified as adverse drug rxns (343) https://t.co/tpUPDc8x09 https://t.co/jdssH7oCjF
Dr. John Cush @RheumNow ( View Tweet )
2 years 2 months ago
UK study 336 GCA pts shows after 12 mos of tocilizumab, TCZ stopped (w mean pred 2mg/d) & GCA flares at 6, 12 & 24 mos was 21%, 35% & 49% respectively; requiring prednisolone dose increase to 20 (10-40) mg/day (34% were major relapses) https://t.co/EZ78ciNK0R https://t.co/R1qFsvnhoF
Dr. John Cush @RheumNow ( View Tweet )
2 years 2 months ago
"Protein kinases: drug targets for immunological disorders". Great full-read review from J Shea et al. Reviews Hx, biology, clinical use and safetey of Kinase targeted therapy. https://t.co/qBc0ng1Z9h https://t.co/Qm8PFpNxQF
Dr. John Cush @RheumNow ( View Tweet )
2 years 2 months ago
NEJM Clinical Images: Scleromyxedema (cutaneous mucinosis w/ a paraproteinemia).53-yoM w/ itchy rash, Raynauds, dysphagia, burning dysesthesia hands; Waxy papules across forehead & hands w/ skin thickening & finger contractures. Skin Bx & SPEP done https://t.co/vkpYGNd3Uw https://t.co/T5gVPRBrhh
Dr. John Cush @RheumNow ( View Tweet )
2 years 2 months ago
Cancer and TNF inhibitors Cancer risk minimisation is a high priority for people with rheumatic diseases, as it is for the general population. Tumor necrosis factor inhibitors (TNFi) have a long history of association with cancer risk discussions https://t.co/iWnBTqX1eV https://t.co/lDEyM0c2yo
Dr. John Cush @RheumNow ( View Tweet )
2 years 2 months ago

How early is early in psoriatic arthritis? Is there a window of opportunity for treatment in PsA to ensure optimal outcomes? https://t.co/jHrA1M05Qr https://t.co/jcU13Y4CRm

Dr. John Cush @RheumNow ( View Tweet )
2 years 2 months ago
×